June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Significance of Drusen Regression in Intermediate Age-Related Macular Degeneration (AMD) in Progression to Advanced Disease
Author Affiliations & Notes
  • Tanya Glaser
    National Eye Institute, National Institutes of Health (NIH), Bethesda, MD
    School of Medicine, University of California - San Francisco, San Francisco, CA
  • E Lauren Doss
    National Eye Institute, National Institutes of Health (NIH), Bethesda, MD
    School of Medicine, University of California - San Francisco, San Francisco, CA
  • Elvira Agrón
    National Eye Institute, National Institutes of Health (NIH), Bethesda, MD
  • Divya Nigam
    National Eye Institute, National Institutes of Health (NIH), Bethesda, MD
  • Emily Chew
    National Eye Institute, National Institutes of Health (NIH), Bethesda, MD
  • Wai Wong
    Office of the Scientific Director, National Eye Institute, National Institutes of Health (NIH), Bethesda, MD
  • Footnotes
    Commercial Relationships Tanya Glaser, None; E Lauren Doss, None; Elvira Agrón, None; Divya Nigam, None; Emily Chew, None; Wai Wong, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4151. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Tanya Glaser, E Lauren Doss, Elvira Agrón, Divya Nigam, Emily Chew, Wai Wong; Significance of Drusen Regression in Intermediate Age-Related Macular Degeneration (AMD) in Progression to Advanced Disease. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4151.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To investigate the prognostic implications of drusen regression (DrR) in eyes with intermediate AMD for progression to advanced AMD.

Methods: Participants at the NEI site of the Age-Related Eye Disease Study 2 (AREDS2) who met enrollment criteria (aged 50 years and older, and with large drusen (≥125 µm) in both eyes or large drusen in one eye and advanced disease in the fellow eye) were prospectively followed with annual color and monochromatic fundus photography and fundus autofluorescence (FAF) imaging for five years. Eyes not progressing to advanced disease by year 2 were identified and analyzed, with each participant contributing at most one eye. Annual multimodal images were spatially aligned using i2k Retina Software (DualAlign LLC, Clifton Park). The occurrence and location of significant DrR (area >125 µm) between baseline and year 2 were detected and outlined using computer-assisted image analysis. For eyes progressing to advanced AMD, areas of CGA on mFC FAF imaging and areas of late fluorescein angiography leakage were manually delineated by planimetry.

Results: Out of fifty-eight eyes from 58 patients with intermediate AMD and large drusen, 31 (53%) demonstrated significant DrR between baseline and year 2. Annual follow up showed that rates of progression to advanced AMD (CGA or nvAMD) for eyes with DrR vs. without DrR were: 23% (7/30) vs. 7% (2/27) by year 3; 32% (9/28) vs. 11% (4/28) by year 4; and 38% (9/24) vs. 17% (4/24) by year 5. Progression to CGA by year 5 was 17% (4/24) vs. 0% (0/23), while progression to nvAMD by year 5 was 21% (5/24) vs. 17% (4/23). Hazard ratios for progression to advanced AMD (CGA or CNV), and to nvAMD were 2.47 (p = 0.15) and 1.23 (p = 0.75) respectively. The mean percentage of DrR areas that developed subsequent GA was 59±33% and the mean probability of colocalization relative to chance was 10.4 (0.9 - 31).

Conclusions: Significant DrR is a common occurrence in eyes with intermediate AMD. Eyes demonstrating significant DrR may be at increased risk for short-term progression to GA, relative to eyes without DrR. The high probability of overlap between areas of GA and DrR suggests that areas of DrR may be locally predisposed to the formation of GA, and that DrR constitutes an early step in local events leading to AMD advancement.

Keywords: 412 age-related macular degeneration • 504 drusen  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×